334 related articles for article (PubMed ID: 8855178)
1. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
Fromm MF; Busse D; Kroemer HK; Eichelbaum M
Hepatology; 1996 Oct; 24(4):796-801. PubMed ID: 8855178
[TBL] [Abstract][Full Text] [Related]
2. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
3. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
Holtbecker N; Fromm MF; Kroemer HK; Ohnhaus EE; Heidemann H
Drug Metab Dispos; 1996 Oct; 24(10):1121-3. PubMed ID: 8894514
[TBL] [Abstract][Full Text] [Related]
4. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects.
Murthy SS; Nelson WL; Shen DD; Power JM; Cahill CM; McLean AJ
Drug Metab Dispos; 1991; 19(6):1093-100. PubMed ID: 1687016
[TBL] [Abstract][Full Text] [Related]
6. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Villikka K; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
[TBL] [Abstract][Full Text] [Related]
7. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
8. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans.
Glaeser H; Drescher S; Hofmann U; Heinkele G; Somogyi AA; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2004 Sep; 76(3):230-8. PubMed ID: 15371984
[TBL] [Abstract][Full Text] [Related]
9. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.
Tannergren C; Engman H; Knutson L; Hedeland M; Bondesson U; Lennernäs H
Clin Pharmacol Ther; 2004 Apr; 75(4):298-309. PubMed ID: 15060508
[TBL] [Abstract][Full Text] [Related]
10. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
[TBL] [Abstract][Full Text] [Related]
11. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
Dilger K; Hofmann U; Klotz U
Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
[TBL] [Abstract][Full Text] [Related]
12. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action.
Mikus G; Eichelbaum M; Fischer C; Gumulka S; Klotz U; Kroemer HK
J Pharmacol Exp Ther; 1990 Jun; 253(3):1042-8. PubMed ID: 2359015
[TBL] [Abstract][Full Text] [Related]
13. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction.
Ling S; Jamali F
Basic Clin Pharmacol Toxicol; 2009 Jul; 105(1):24-9. PubMed ID: 19371259
[TBL] [Abstract][Full Text] [Related]
14. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH
Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
[TBL] [Abstract][Full Text] [Related]
15. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
16. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
17. Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies.
Ling S; Jamali F
Drug Metab Dispos; 2005 Apr; 33(4):579-86. PubMed ID: 15659540
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
19. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Choi DH; Chang KS; Hong SP; Choi JS; Han HK
Biopharm Drug Dispos; 2008 Jan; 29(1):45-50. PubMed ID: 17941000
[TBL] [Abstract][Full Text] [Related]
20. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.
Karim A; Piergies A
Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
